Major award for world-leaders in melanoma research

Major award for world-leaders in melanoma research

9 November 2018

Melanoma Institute Australia’s (MIA) Co-Medical Directors have won the prestigious GSK Award for Research Excellence at Research Australia’s Health and Medical Research Awards.

Professor Georgina Long and Professor Richard Scolyer have been recognised as world leaders in melanoma research for their ground-breaking work that has changed the diagnosis and treatment landscape of melanoma world-wide, and tripled the life-expectancy of advanced melanoma patients.

Professor Long and Professor Scolyer believe that with the advancement of both immune- and targeted therapies (those treatments that utilise patients’ immune systems to fight cancer or alter the function of specific genes to arrest the growth of cancer) we are now realistically looking towards achieving zero deaths from melanoma within their lifetimes.

“As Australians, we’re proud of the success our country has had in leading the fight against melanoma but there’s still much more to do and discover. There’s a critical need to better understand why some melanomas develop so we can improve prevention and treatment,” said Professor Scolyer.

“While we do have these breakthrough therapies, there are still a group of patients who are resistant,” added Professor Long. “We’re starting to understand why patients develop resistance – and if we can tackle this by individualising and targeting therapy, we will impact not only melanoma but all cancers.”

Professor Long and Professor Scolyer said that winning the GSK Award for Research Excellence highlights the importance of recognising Australian successes in the research space, and is testament to the power of collaboration that MIA strives to emphasise in its work.

“Collaboration is vital for big research steps and gains. For us, this award recognises not only our team, but the collaborative efforts of our predecessors, colleagues, industry and patients,” said Professor Long. “We stand on the shoulders of others’ foresight and hard work, as well as the generosity of Australian patients whose participation in clinical trials is critical to scientific discovery.”

“It’s important that Australian science and research success is celebrated, and we are grateful to be a part of that story. We are honoured and humbled to have received this award as we, and our team, work hard to impact the lives of patients all over the world,” said Professor Scolyer.

Dr. Andrew Weekes, Medical Director of GSK, said; “The work of Professors Long and Scolyer is an outstanding example of how home-grown innovation and collaboration can impact the lives of patients around the world. We are honoured to recognise their achievements and support research which could underpin further discoveries and better outcomes for patients.”

The GSK Award for Research Excellence is one of the most prestigious awards available to the Australian medical research community. It has been awarded since 1980 to recognise outstanding achievements in medical research with potential importance to human health.

The GSK Award comes just a week after MIA’s Co-Medical Directors, and their fellow researchers Associate Professor Alex Menzies and Associate Professor Anne Cust, received top awards at the NSW Premier’s Awards for Outstanding Cancer Research.

Announcement from Melanoma Institute Australia
24 Nov 2016

Announcement from Melanoma Institute Australia

After 18 years as Director of the Sydney Melanoma Unit and then Executive Director of Melanoma Institute Australia, Professor John Thompson AO will step down from the position at the end of 2016.

Nine practice points from the new melanoma guidelines
17 Nov 2016

Nine practice points from the new melanoma guidelines

Australian melanoma clinical practice guidelines have been published on a wiki platform for the first time as researchers try to keep up to date with emerging evidence.  

Melanoma under 40
17 Nov 2016

Melanoma under 40

Carole Renouf, CEO of Melanoma Institute Australia is asking young Australians who have been affected by melanoma to share their experiences with her.

Don't let sunburn be your summer holiday souvenir
11 Nov 2016

Don't let sunburn be your summer holiday souvenir

Melanoma Institute Australia CEO Carole Renouf wants to make sure Aussies remember to take care of our skin as the festive season draws closer and we spend more time in the sun.

Using clinical features to identify patients at high risk for melanoma
10 Nov 2016

Using clinical features to identify patients at high risk for melanoma

Can an individual’s risk factors for melanoma be used to tailor skin self-examinations and surveillance programs?

MIA congratulates Professor Georgina Long
09 Nov 2016

Congratulations to Professor Georgina Long

Prof Georgina Long has been appointed President-Elect Society for Melanoma Research (SMR).

Tags: more news
Uniting our global researchers for melanoma
28 Oct 2016

Uniting our global researchers for melanoma

The Australasian Melanoma Conference is bringing together some of the world's leading researchers and clinicians.

Best practice guidelines for melanoma care go digital
28 Oct 2016

Best practice guidelines for melanoma care go digital

Best practice guidelines for melanoma care have gone digital with the first-ever online guidelines developed to adapt to the rapid change in clinical management.

Awards and honours for our talented researchers
26 Oct 2016

Awards and honours for our talented researchers

Congratulations are in order for two of our talented researchers.

5 Minutes With Prof Richard Scolyer
21 Oct 2016

5 Minutes With Prof Richard Scolyer

Professor Richard Scolyer will be sharing his expertise on melanoma pathology at the upcoming Australasian Melanoma Conference. Here he discusses what he'll be presenting on. 

Research spotlight: High Risk Clinic
10 Oct 2016

Research spotlight: High Risk Clinic

Researchers at MIA have established a High Risk Clinic to monitor people at very high risk of developing melanoma.

Learning from the best in the world
05 Oct 2016

Learning from the best in the world

A generous donation has enabled a medical oncologist from Portugal to learn from the best in the world at MIA.

Uniting the world for a cure
30 Sep 2016

Uniting the world for a cure

MIA is hosting a conference to bring together greats minds in melanoma research that will make a difference to the lives of melanoma patients

A Day in the Life of... Michelle Peranec
30 Sep 2016

A Day in the Life of... Michelle Peranec

Meet Michelle, our Translational Research Officer whose role is to connect the clinics to the lab by ensuring patient blood and tissue samples are documented and carefully stored in our BioSpecimen Bank.

Wildfire Award helps ignite new melanoma research
08 Sep 2016

Wildfire Award helps ignite new melanoma research

Dr James Wilmott says his Wildfire Award will help expand research into treatment options for people with mucosal melanoma, a rare but deadly form of skin cancer.

Opinion: Fighting the Resistance
25 Aug 2016

Opinion: Fighting the Resistance

Following the recent hype around immunotherapies in cancer, CEO Carole Renouf shares the greatest story never told… resistance… and what MIA is doing to address it.

5 Minutes With A/Prof Jennifer Wargo
11 Aug 2016

5 Minutes With A/Prof Jennifer Wargo

A/Prof Wargo discusses the research she will be presenting as a keynote speaker at the upcoming Australasian Melanoma Conference.

Dr James Wilmott awarded for outstanding cancer research
06 Aug 2016

Dr James Wilmott awarded for outstanding cancer research

Dr James Wilmott has been awarded the Wildfire award at this year's Cancer Institute NSW's Premier Awards for Outstanding Cancer Research.

Community invests in MIA's new trial
19 Jul 2016

Community invests in MIA's new trial

The community has responded generously to our recent appeal to fund a specialised nursing position in an exciting new clinical trial. 

New trial giving options
18 Jul 2016

New trial giving options

We have developed a unique clinical trial that will use existing drugs to target rare genes in melanoma patients.